These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 520652)

  • 1. Hexopal in Raynaud's disease.
    Aylward M
    J Int Med Res; 1979; 7(6):484-91. PubMed ID: 520652
    [No Abstract]   [Full Text] [Related]  

  • 2. An experimentally controlled evaluation of the effect of inositol nicotinate upon the digital blood flow in patients with Raynaud's phenomenon.
    Holti G
    J Int Med Res; 1979; 7(6):473-83. PubMed ID: 391622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of vasodilator agents and of indirect heating in Raynaud's disease.
    Hansteen V
    Scand J Clin Lab Invest Suppl; 1973; 128():211-2. PubMed ID: 4764583
    [No Abstract]   [Full Text] [Related]  

  • 4. A double blind randomised placebo controlled trial of hexopal in primary Raynaud's disease.
    Sunderland GT; Belch JJ; Sturrock RD; Forbes CD; McKay AJ
    Clin Rheumatol; 1988 Mar; 7(1):46-9. PubMed ID: 3044673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A plethysmographic study of the effect of tetranicotinoylfructose (Bradilan) on digital blood flow in primary and secondary Raynaud's phenomenon.
    Antcliff AC; Bouhoutsos J; Martin P; Morris T
    Angiology; 1974 May; 25(5):312-6. PubMed ID: 4823806
    [No Abstract]   [Full Text] [Related]  

  • 6. [The influence of isosorbide mononitrate on skin blood flow in patients with Raynaud's syndrome].
    Gross R; Galus K; Zajac S; Jedrasik M
    Wiad Lek; 2002; 55(1-2):29-34. PubMed ID: 12043312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of vasodilator therapy for severe Raynaud's phenomenon by sequential arterial infusion.
    Russell IJ; Walsh RA
    Ann Rheum Dis; 1985 Mar; 44(3):151-4. PubMed ID: 3977418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Sympatholytic effect of intra-arterial reserpine in sclerodermia and Raynaud's disease].
    Acevedo A; Palacios JM; López R; Palma F
    Rev Med Chil; 1984 Jun; 112(6):553-8. PubMed ID: 6515168
    [No Abstract]   [Full Text] [Related]  

  • 10. [Study of the plethysmographic amplification factor during vasodilator treatment. Healthy subject versus primary Raynaud phenomenon].
    Lasfargues G; Royere D; Perrotin D; Titon JP; Soutif D; Guilmot JL
    J Mal Vasc; 1987; 12(4):319-22. PubMed ID: 3694055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of a-sympathicolysis in Raynaud's syndrome].
    Westermann KW; Langbehn A; Feige A; Priester G
    Verh Dtsch Ges Inn Med; 1973; 79():1395-7. PubMed ID: 4275201
    [No Abstract]   [Full Text] [Related]  

  • 12. Microcirculatory changes in patients with primary Raynaud's phenomenon after treatment with buflomedil.
    Jacobs MJ; Lemmens HA
    Int J Microcirc Clin Exp; 1985; 4(1):63-8. PubMed ID: 3886577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasodilator refractoriness in Raynaud's syndrome.
    Sarkany I; Tan OT; Gaylarde PM
    Clin Exp Dermatol; 1982 Nov; 7(6):679-80. PubMed ID: 7151321
    [No Abstract]   [Full Text] [Related]  

  • 14. Iloprost treatment in pediatric patients with complicated Raynaud's phenomenon.
    Cekic S; Kilic SS
    Lupus; 2016 Apr; 25(5):558-60. PubMed ID: 26692039
    [No Abstract]   [Full Text] [Related]  

  • 15. [Laser Doppler spectral analysis of patients with Raynaud's phenomenon during a standardized thermal test].
    Léger P
    Ann Dermatol Venereol; 1998 Nov; 125 Suppl 2():S28-9. PubMed ID: 9922888
    [No Abstract]   [Full Text] [Related]  

  • 16. Topical nitroglycerin ointment in Raynaud's phenomenon.
    Fischer M; Reinhold B; Falck H; Török M; Alexander K
    Z Kardiol; 1985 May; 74(5):298-302. PubMed ID: 3925656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of Raynaud's syndrome with captopril].
    Trübestein G; Wigger E; Trübestein R; Ludwig M; Wilgalis M; Stumpe KO
    Dtsch Med Wochenschr; 1984 Jun; 109(22):857-60. PubMed ID: 6373219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative thermal imaging to assess inositol nicotinate treatment for Raynaud's syndrome.
    Ring EF; Porto LO; Bacon PA
    J Int Med Res; 1981; 9(6):393-400. PubMed ID: 7319129
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of Raynaud's phenomenon by fibrinolytic enhancement.
    Jarrett PE; Morland M; Browse NL
    Br Med J; 1978 Aug; 2(6136):523-5. PubMed ID: 698554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recount of prostaglandin E1 therapy in a patient with Raynaud's phenomenon.
    DiGiovanni RL; Littlefield JM; Good RG
    J Am Osteopath Assoc; 1995 Oct; 95(10):572. PubMed ID: 8557544
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.